UNSPSC 51282918: Fleroxacin

This classification denotes a quinolone antibiotic with the molecular formula C17H18F3N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N804LDH51K, chemically known as 6,8-difluoro-1-(2-fluoroethyl)-1,4-dihydro-7-(4-methylpiperazino)-4-oxo-3-quinolinecarboxylic acid but generally known as fleroxacin, which bears US NIH Compound Identifier 3357. European Medicines Agency schedules Fleroxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07639MIG.

UNSPSC 51282918 Fleroxacin, a Commodity code, shows minimal recent state and local procurement activity aligned with its nominal scope. The two most recent opportunities tagged under this code involve pharmaceutical procurement, but neither involves fleroxacin directly: the Illinois Department of Public Health awarded a piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for doxycycline hyclate and ciprofloxacin hydrochloride tablets totaling $2,999,999.11 over three years; and Seminole County, Florida issued an IFB on June 30, 2026, for naloxone and drug deactivation systems with quarterly deliveries and a two-year initial term plus one-year renewal option. State and local procurement under this code appears driven by health departments and county health agencies using cooperative purchasing consortia and competitive bidding to source antibiotics and emergency medical supplies through established frameworks rather than open-market solicitation for fleroxacin as a named product line.

Activity is concentrated in Florida and Illinois based on recent postings, though the sample is too small to characterize broader geographic patterns. The Illinois contract represents the larger transaction value and a multi-year commitment through a state health department; the Seminole County opportunity reflects local government health services procurement with FEMA compliance considerations. Neither opportunity specifies set-aside designations or disadvantaged-enterprise preferences. Business development activity under this code should focus on establishing relationships with state departments of health and county health agencies using pharmaceutical cooperative purchasing vehicles such as MMCAP Infuse, and positioning fleroxacin supply within standing master agreements rather than pursuing individual commodity spot buys.